...BRCA1 and 63 (5.10%) were in BRCA2. LGRs accounted for 6.67% (8 of 120) of all BRCA mutations, whereas 8.77 % (5 of 57) ...
...BRCA1 and BRCA2 were more dramatically altered by Hsp90 inhibitors and DDP in combination compared to Hsp90 inhibitors o...
...BRCA1 recruitment but at 8 h post IR, BRCA1 foci are smaller and aberrantly positioned compared to control cells. BRCA1 ...
...BRCA1 germline mutations. In the second year of prospective PDAC screening, one neuroendocrine tumour and a high-grade d...
...BRCA1/2 mutation according to the Manchester scoring system, a validated method to assess the likelihood of mutation det...
...BRCA1, and p53 protein expression was not significantly different between the Raf-1-positive and Raf-1-negative expressi...
...BRCA1 in homologous recombination (HR), have demonstrated to further sub-classify low BRCA1 NSCLC tumors, improving the ...
...BRCA1-A complex, influenced outcome in patients with low BRCA1 expression treated with cisplatin/gemcitabine, and in pat...
...BRCA1) are among the most promising potential biomarkers for early disease and their clinical utility is currently being...
...BRCA1 and BRCA2 in 135 breast and/or ovarian cancer patients. Deleterious BRCA1 and BRCA2 mutations were detected in 10 ...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2026.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
